Intellectual Property - November 13, 2017
OxThera granted new patents
OxThera has recently been granted two new US patents, three new Europeanpatents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate decarboxylase. The new European patents have numbers EP2449098 covering pharmaceutical compositions of oxalate decarboxylase, EP1771201 and EP1965816 covering pharmaceutical compositions of Oxalobacter formigenes. […]
In a new job - October 17, 2017
Bastian Dehmel appointed new CMO of OxThera
OxThera announces the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer. Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgen’s calcimimetic franchise. He has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease. Bastian […]
In a new job - August 4, 2017
New CEO of OxThera
OxThera has appointed Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal […]
Drug Development Pharma - September 23, 2014
Oxabact granted EMA orphan drug designation
OxThera AB’s product Oxabact has been granted an Orphan Drug Designation in the European Union for treatment of Short Bowel Syndrome (SBS). Oxabact is an oral product composed of highly concentrated live bacteria (Oxalobacter formigenes). OxThera is currently pursuing a clinical development program in the EU and in the US for the treatment of patients suffering from Primary […]